Quick Answer
Insight Molecular Diagnostics Inc. reported Total Revenue of $4.05 million for fiscal year 2025.
Insight Molecular Diagnostics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $4.05M +115.6% |
$1.88M +25.1% |
$1.50M +56.9% |
$958.0K -56.4% |
$2.20M +80.8% |
$1.22M |
| Revenue (ASC 606) | $4.05M +115.6% |
$1.88M +25.1% |
$1.50M +56.9% |
$958.0K -56.4% |
$2.20M +80.8% |
$1.22M |
| Net Income | -$50.22M +17.2% |
-$60.66M -118.4% |
-$27.78M +61.9% |
-$72.90M -13.7% |
-$64.10M -114.1% |
-$29.93M -33.5% |
| Diluted EPS | -$1.65 +64.6% |
-$4.66 -24.3% |
-$3.75 +71.7% |
-$13.25 | — | — |
| Total Assets | $25.76M -26.6% |
$35.08M -53.2% |
$74.89M -25.2% |
$100.09M -37.3% |
$159.56M +187.9% |
$55.42M +39.0% |
| Cash and Equivalents | $11.58M +34.1% |
$8.64M -8.4% |
$9.43M -52.8% |
$19.99M -39.3% |
$32.95M +361.3% |
$7.14M -67.6% |
| Stockholders Equity | -$31.46M -156.3% |
-$12.27M -160.0% |
$20.47M -40.3% |
$34.29M -47.4% |
$65.22M +94.8% |
$33.48M +8.6% |
| R&D Expense | $15.90M +61.6% |
$9.84M +5.9% |
$9.29M +27.3% |
$7.30M +45.0% |
$5.04M -48.6% |
$9.80M +44.2% |
| Operating Income | -$51.12M +16.2% |
-$61.04M -142.8% |
-$25.14M -39.7% |
-$18.00M +66.5% |
-$53.73M -80.8% |
-$29.71M -33.6% |
| Gross Profit | $2.30M +210.5% |
$740.0K +79.2% |
$413.0K +2394.4% |
-$18.0K -101.3% |
$1.42M +322.2% |
-$639.0K |
| Shares Outstanding | 28.68M +64.3% |
17.45M +111.3% |
8.26M +39.3% |
5.93M -93.6% |
92.23M +33.4% |
69.12M +21.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $260.0K | +126.1% | -49.8% |
| Revenue (ASC 606) | September 30, 2025 | $260.0K | +126.1% | -49.8% |
| Net Income | September 30, 2025 | -$10.85M | +19.6% | -11.4% |
| Diluted EPS | September 30, 2025 | -$0.34 | +65.3% | -13.3% |
| Total Assets | September 30, 2025 | $43.94M | -37.4% | -13.0% |
| Cash and Equivalents | September 30, 2025 | $18.69M | +455.8% | -23.0% |
| Stockholders Equity | September 30, 2025 | -$9.20M | -194.7% | -937.5% |
| R&D Expense | September 30, 2025 | $3.88M | +37.7% | +18.2% |
| Operating Income | September 30, 2025 | -$11.05M | +18.3% | -12.3% |
| Gross Profit | September 30, 2025 | $139.0K | +178.0% | -60.3% |
| Shares Outstanding | September 30, 2025 | 28.63M | +114.0% | +0.0% |
- Insight Molecular Diagnostics Inc. reported Total Revenue of $4.05 million for fiscal year 2025.
- Insight Molecular Diagnostics Inc. showed an increase of +115.6% in Total Revenue compared to the prior fiscal year.
- Insight Molecular Diagnostics Inc. reported Revenue (ASC 606) of $4.05 million for fiscal year 2025.
- Insight Molecular Diagnostics Inc. showed an increase of +115.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Insight Molecular Diagnostics Inc. reported Net Income of -$50.22 million for fiscal year 2025.
- Insight Molecular Diagnostics Inc. showed an increase of +17.2% in Net Income compared to the prior fiscal year.
- Insight Molecular Diagnostics Inc. reported Diluted EPS of $1.65 per share (loss) for fiscal year 2025.
- Insight Molecular Diagnostics Inc. showed an increase of +64.6% in Diluted EPS compared to the prior fiscal year.
- Insight Molecular Diagnostics Inc. reported Total Assets of $25.76 million for fiscal year 2025.
- Insight Molecular Diagnostics Inc. showed a decrease of -26.6% in Total Assets compared to the prior fiscal year.
- Insight Molecular Diagnostics Inc. reported Cash and Equivalents of $11.58 million for fiscal year 2025.
- Insight Molecular Diagnostics Inc. showed an increase of +34.1% in Cash and Equivalents compared to the prior fiscal year.
- Insight Molecular Diagnostics Inc. reported Stockholders Equity of -$31.46 million for fiscal year 2025.
- Insight Molecular Diagnostics Inc. showed a decrease of -156.3% in Stockholders Equity compared to the prior fiscal year.
- Insight Molecular Diagnostics Inc. reported R&D Expense of $15.90 million for fiscal year 2025.
- Insight Molecular Diagnostics Inc. showed an increase of +61.6% in R&D Expense compared to the prior fiscal year.
- Insight Molecular Diagnostics Inc. reported Operating Income of -$51.12 million for fiscal year 2025.
- Insight Molecular Diagnostics Inc. showed an increase of +16.2% in Operating Income compared to the prior fiscal year.
- Insight Molecular Diagnostics Inc. reported Gross Profit of $2.30 million for fiscal year 2025.
- Insight Molecular Diagnostics Inc. showed an increase of +210.5% in Gross Profit compared to the prior fiscal year.
- Insight Molecular Diagnostics Inc. reported Shares Outstanding of 28.68 million shares for fiscal year 2025.
- Insight Molecular Diagnostics Inc. showed an increase of +64.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: